Oncolys BioPharma Secures Japan Approval for Telomelysin in Esophageal Cancer
TOKYO, Japan, June 8, 2026 Oncolys BioPharma has achieved a major milestone in cancer treatment innovation with the Japanese...
AI drug discovery artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
TOKYO, Japan, June 8, 2026 Oncolys BioPharma has achieved a major milestone in cancer treatment innovation with the Japanese...
WASHINGTON, D.C., United States, June 9, 2026 The U.S. Food and Drug Administration (FDA) has approved the addition of...
